본문으로 건너뛰기
← 뒤로

Improving immunotherapy in solid tumors using FMT.

2/5 보강
Cell 📖 저널 OA 50% 2024: 1/1 OA 2025: 2/6 OA 2026: 15/28 OA 2024~2026 2026 Vol.189(8) p. 2214-2217 Immunotherapy and Immune Responses
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-29
OpenAlex 토픽 · Immunotherapy and Immune Responses Cancer Research and Treatments Monoclonal and Polyclonal Antibodies Research

Davar D, Zarour HM, Trinchieri G

📝 환자 설명용 한 줄

Recent clinical trials demonstrate that fecal microbiota transplantation (FMT) enhances first-line immune checkpoint inhibitor efficacy in renal cell carcinoma, cutaneous melanoma, and non-small cell

이 논문을 인용하기

↓ .bib ↓ .ris
APA Diwakar Davar, Hassane M. Zarour, Georgio Trinchieri (2026). Improving immunotherapy in solid tumors using FMT.. Cell, 189(8), 2214-2217. https://doi.org/10.1016/j.cell.2026.03.021
MLA Diwakar Davar, et al.. "Improving immunotherapy in solid tumors using FMT.." Cell, vol. 189, no. 8, 2026, pp. 2214-2217.
PMID 41997122 ↗

Abstract

Recent clinical trials demonstrate that fecal microbiota transplantation (FMT) enhances first-line immune checkpoint inhibitor efficacy in renal cell carcinoma, cutaneous melanoma, and non-small cell lung cancer with acceptable safety. Benefit appears mediated by functional microbiome remodeling, depletion of deleterious taxa, and systemic immunometabolic modulation, supporting microbiome-directed therapeutic strategies for cancer immunotherapy.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반